drugset / Trial / NCT05626634
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.
Timeline
- Start
- 2022-11-08
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bexicaserin | Small molecule | 6 mg | Oral |
| Subject | bexicaserin | Small molecule | 9 mg | Oral |
| Subject | bexicaserin | Small molecule | 12 mg | Oral |